Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
Executive Summary
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.